Amphastar Pharmaceuticals Inc (AMPH) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)
 

Amphastar Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMPH Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 8.22 % 14.14 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 12.89 % -1.07 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 2.85 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 2.16 % 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 15.53 % 7.52 % 8.67 % 13.63 %


AMPH's Growth Comparisons in III. Quarter 2026




Comparing 8.22% year on year top-line growth in the third quarter 2026, Amphastar Pharmaceuticals Inc grew on the lower pace than the 14.14% rise in the Major Pharmaceutical Preparations industry and 10.18% Revenue improvement in the Healthcare sector. Comparing the third quarter, sales Amphastar Pharmaceuticals Inc was trailing overall market not just Major Pharmaceutical Preparations industry.

Top-line improved by 12.89% from the second quarter. Looking into annual sales rise of 15.53%, and S & P 500's average yearly sales growth is 13.63% over the five years, including only Businesses with the third quarter 2026 Results. Amphastar Pharmaceuticals Inc grew faster than the market.

AMPH Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Primatenemist
-
61.97 %
Contract Manufacturing Services
-
88.57 %
BAQSIMI
-
200 %
Epinephrine
-
43.55 %
Lidocaine
-
58.38 %
Glucagon
-
40.69 %
Ipratropium Bromide
-
79 %
Other Products
-
52.67 %
Finished Pharmaceutical Products Segment
193.31 %
58.47 %
US
-
57.6 %
CN
-
87.56 %
FR
-
63.5 %
Total
8.22 %
12.89 %


Growth Rates of AMPH's Income in the third quarter 2026


AMPH Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 100.53 % 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) 27.8 % -23.95 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) 5.48 % 30.78 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) 22.27 % -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change 66.56 % 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) 117.65 % -16.85 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 24.43 % -26.31 % -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) -11.35 % 6.26 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) 25.99 % -9.98 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 145.63 % 14.58 % 8.91 % -28.64 %

AMPH Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) 117.65 % -17.47 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) 24.43 % 21.94 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) -11.35 % 5.06 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) 25.99 % -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth 145.63 % 14.16 % 9.09 % 23.95 %

AMPH's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) 134.21 % -31.09 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 28.99 % -35.27 % -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) -4.68 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) 29.48 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 133.89 % -0.46 % 8.91 % -28.64 %



AMPH EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) 135.14 % -31.6 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) 29.85 % 7.1 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) 29.59 % 0.05 % 10.63 % 4.93 %
EPS Net 5 Year Avg. Change 132.31 % 14.16 % 9.09 % 23.95 %



Despite the -31.6% decline in Major Pharmaceutical Preparations industry, Amphastar Pharmaceuticals Inc showed impressive surge in EPS in the third quarter by 135.14% from the same quarter a year ago, to $0.87, Healthcare sector dropped -39.2%. Despite modest earnings per share in the Major Pharmaceutical Preparations industry and ind the Healthcare sector, Amphastar Pharmaceuticals Inc reported above average market earnings per share growth.

The company's sequential bottom-line increase was 29.85% from the second quarter. Average annual income per share rise for Amphastar Pharmaceuticals Inc is 132.31%, while S & P 500's average yearly income per share growth is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings results.

AMPH Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 25.56 % 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) - -29.98 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) -59.9 % 12.44 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) -70.88 % 3.57 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change 38.42 % 0.88 % 0.41 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -0.41 % 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) 1852.9 % 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) 1115.7 % -21.14 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) 216.96 % 15.58 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) 312.42 % 1.87 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change 1.87 % 7.84 % 8.61 % 14.19 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.